NEW YORK, May 29, 2015 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amedisys, Inc. ("Amedisys" or the "Company") (NASDAQ: AMED). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 237.
The investigation concerns whether Amedisys and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On May 28, 2015, the Company announced in an Securities and Exchange Commission (SEC) filing that, "on May 21, 2015, it received a Subpoena Duces Tecum ("Subpoena") issued by the U.S. Department of Justice. The Subpoena requests the delivery of information regarding 53 identified hospice patients to the United States Attorney's Office for the District of Massachusetts. It also requests the delivery of documents relating to the Company's hospice clinical and business operations and related compliance activities. The Subpoena generally covers the period from January 1, 2011, through the present."
On this news, shares of Amedisys fell $1.14 per share, to 30.69, or more than 3.58%, on May 29, 2015.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
Robert S. Willoughby
SOURCE Pomerantz LLP